EyePoint Pharmaceuticals (EYPT) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

EyePoint Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$43.27M

Latest Revenue (Q)

$5.33M

Main Segment (Y)

License And Collaboration Agreement

Main Geography (Y)

UNITED STATES

EyePoint Pharmaceuticals Revenue by Period

EyePoint Pharmaceuticals Revenue by Year

Date	Revenue	Change
2024-12-31	$43.27M	-5.97%
2023-12-31	$46.02M	11.14%
2022-12-31	$41.40M	12.09%
2021-12-31	$36.94M	7.27%
2020-12-31	$34.44M	69.10%
2019-12-31	$20.36M	587.77%
2018-06-30	$2.96M	-60.72%
2017-06-30	$7.54M	365.37%
2016-06-30	$1.62M	-93.90%
2015-06-30	$26.57M	664.90%
2014-06-30	$3.47M	62.06%
2013-06-30	$2.14M	-39.22%
2012-06-30	$3.53M	-28.98%
2011-06-30	$4.96M	-78.46%
2010-06-30	$23.05M	89.55%
2009-06-30	$12.16M	249.88%
2008-06-30	$3.48M	55.53%
2007-06-30	$2.23M	52.52%
2006-06-30	$1.47M	132.78%
2005-06-30	$629.52K	137.35%
2004-06-30	$265.23K	256.73%
2003-06-30	$74.35K	-85.60%
2002-06-30	$516.32K	-

EyePoint Pharmaceuticals generated $43.27M in revenue during NA 2024, up -5.97% compared to the previous quarter, and up 212.49% compared to the same period a year ago.

EyePoint Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-06-30	$5.33M	-78.19%
2025-03-31	$24.45M	111.02%
2024-12-31	$11.59M	10.11%
2024-09-30	$10.52M	11.05%
2024-06-30	$9.48M	-18.89%
2024-03-31	$11.68M	-16.71%
2023-12-31	$14.03M	-7.72%
2023-09-30	$15.20M	66.96%
2023-06-30	$9.11M	18.51%
2023-03-31	$7.68M	-27.06%
2022-12-31	$10.53M	5.20%
2022-09-30	$10.01M	-13.43%
2022-06-30	$11.56M	24.44%
2022-03-31	$9.29M	-19.49%
2021-12-31	$11.54M	27.43%
2021-09-30	$9.06M	0.51%
2021-06-30	$9.01M	23.08%
2021-03-31	$7.32M	2.69%
2020-12-31	$7.13M	-54.57%
2020-09-30	$15.70M	280.76%
2020-06-30	$4.12M	-44.96%
2020-03-31	$7.49M	-13.25%
2019-12-31	$8.63M	244.08%
2019-09-30	$2.51M	-65.20%
2019-06-30	$7.21M	258.35%
2019-03-31	$2.01M	-17.61%
2018-12-31	$2.44M	402.47%
2018-09-30	$486.00K	-32.03%
2018-06-30	$715.00K	-22.95%
2018-03-31	$928.00K	-0.54%
2017-12-31	$933.00K	142.34%
2017-09-30	$385.00K	-45.08%
2017-06-30	$701.00K	18.81%
2017-03-31	$590.00K	-90.12%
2016-12-31	$5.97M	2055.60%
2016-09-30	$277.00K	-8.88%
2016-06-30	$304.00K	-6.17%
2016-03-31	$324.00K	-38.40%
2015-12-31	$526.00K	12.88%
2015-09-30	$466.00K	13.94%
2015-06-30	$409.00K	24.70%
2015-03-31	$328.00K	-37.04%
2014-12-31	$521.00K	-97.94%
2014-09-30	$25.31M	8566.78%
2014-06-30	$292.00K	-85.34%
2014-03-31	$1.99M	236.49%
2013-12-31	$592.00K	-0.84%
2013-09-30	$597.00K	21.34%
2013-06-30	$492.00K	-4.09%
2013-03-31	$513.00K	-12.31%
2012-12-31	$585.00K	5.79%
2012-09-30	$553.00K	-20.89%
2012-06-30	$699.00K	29.93%
2012-03-31	$538.00K	-14.60%
2011-12-31	$630.00K	-62.03%
2011-09-30	$1.66M	-55.34%
2011-06-30	$3.71M	931.94%
2011-03-31	$360.00K	-13.04%
2010-12-31	$414.00K	-13.03%
2010-09-30	$476.00K	-96.97%
2010-06-30	$15.72M	2952.82%
2010-03-31	$515.00K	-85.00%
2009-12-31	$3.43M	1.48%
2009-09-30	$3.38M	4.96%
2009-06-30	$3.22M	1.90%
2009-03-31	$3.16M	6.50%
2008-12-31	$2.97M	5.84%
2008-09-30	$2.81M	3.81%
2008-06-30	$2.70M	398.71%
2008-03-31	$542.00K	-

EyePoint Pharmaceuticals generated $5.33M in revenue during Q2 2025, up -78.19% compared to the previous quarter, and up 45.64% compared to the same period a year ago.

EyePoint Pharmaceuticals Revenue Breakdown

EyePoint Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
License And Collaboration Agreement	$38.50M	-	-	-	-
Product	$3.16M	-	-	-	-
Royalty	$1.61M	-	-	-	-
Y U T I Q Product	$3.10M	$28.33M	$16.96M	$13.88M	$12.05M
D E X Y C U Product	-	$11.58M	$18.35M	$6.95M	$4.78M

EyePoint Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: License And Collaboration Agreement (83.01%), Product (6.82%), Y U T I Q Product (6.68%), and Royalty (3.48%).

Quarterly Revenue by Product

Product/Service	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
License And Collaboration Agreement	$5.33M	$11.05M	$21.15M	$9.56M	$7.78M	$14.14M	$3.60M	$202.00K	-	-	-	-	-	-	-	-	-	-	-	-
Y U T I Q Product	-	$600.00K	$1.30M	$700.00K	$1.10M	$9.02M	$7.27M	$7.42M	$4.61M	$5.83M	$3.93M	$4.17M	$3.03M	$3.96M	$3.47M	$2.88M	$4.74M	-	-	-
Product	-	$715.00K	$1.43M	$664.00K	$1.07M	$816.00K	$5.27M	$11.19M	$8.59M	$8.74M	$6.68M	$5.76M	$3.71M	-	-	-	-	-	-	-
Royalty	-	$12.69M	$687.00K	$299.00K	$627.00K	$249.00K	$235.00K	$474.00K	-	-	-	-	-	-	-	-	-	-	-	-
D E X Y C U Product	-	-	-	-	-	-	-	$833.00K	$2.45M	$3.90M	$4.40M	$5.35M	$4.66M	$4.57M	$3.77M	$2.72M	$2.29M	$827.00K	$3.14M	-
Collaborative Research And Development	-	-	-	-	-	-	-	-	-	$15.00K	-	-	-	-	-	-	-	-	-	-

EyePoint Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: License And Collaboration Agreement (100.00%).

EyePoint Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
CHINA	$1.12M	$823.00K	$851.00K	$11.71M	$1.12M
UNITED STATES	$42.05M	$40.48M	$35.99M	$22.62M	$19.14M

EyePoint Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (97.40%), and CHINA (2.60%).

Quarterly Revenue by Country

Country	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Royalty	$474.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Y U T I Q Product	$9.02M	$7.27M	$7.42M	$4.61M	$5.83M	$3.93M	$4.17M	$3.03M	$3.96M	$3.47M	$2.88M	$4.74M	$55.00K	$6.71M	-	-
Collaborative Research And Development	-	-	$15.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
D E X Y C U Product	$833.00K	$2.45M	$3.90M	$4.40M	$5.35M	$4.66M	$4.57M	$3.77M	$2.72M	$2.29M	$827.00K	$3.14M	$954.00K	$684.00K	-	-
License And Collaboration Agreement	$202.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	-	-	-	-	$11.19M	$8.59M	$8.74M	$6.68M	$5.76M	$3.71M	$6.71M	$543.00K	-	-	-	-

EyePoint Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 22: Y U T I Q Product (85.67%), D E X Y C U Product (7.91%), Royalty (4.50%), and License And Collaboration Agreement (1.92%).

EyePoint Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
MRVI	Maravai LifeSciences	$259.19M	$47.40M
ANAB	AnaptysBio	$91.28M	$27.77M
PHAT	Phathom Pharmaceuticals	$55.25M	$39.50M
KURA	Kura Oncology	$53.88M	$14.11M
EYPT	EyePoint Pharmaceuticals	$43.27M	$5.33M
TNGX	Tango Therapeutics	$42.07M	$3.18M
PGEN	Precigen	$3.92M	$856.00K
PROK	ProKidney	$76.00K	$221.00K
BCAX	Bicara Therapeutics	-	-
XNCR	Xencor	-	$32.73M
AVBP	ArriVent BioPharma	-	-

EYPT Revenue FAQ

What is EyePoint Pharmaceuticals’s yearly revenue?

EyePoint Pharmaceuticals's yearly revenue for 2024 was $43.27M, representing a decrease of -5.97% compared to 2023. The company's yearly revenue for 2023 was $46.02M, representing an increase of 11.14% compared to 2022. EYPT's yearly revenue for 2022 was $41.4M, representing an increase of 12.09% compared to 2021.

What is EyePoint Pharmaceuticals’s quarterly revenue?

EyePoint Pharmaceuticals's quarterly revenue for Q2 2025 was $5.33M, a -78.19% decrease from the previous quarter (Q1 2025), and a -43.73% decrease year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $24.45M, a 111.02% increase from the previous quarter (Q4 2024), and a 109.29% increase year-over-year (Q1 2024). EYPT's quarterly revenue for Q4 2024 was $11.59M, a 10.11% increase from the previous quarter (Q3 2024), and a -17.39% decrease year-over-year (Q4 2023).

What is EyePoint Pharmaceuticals’s revenue growth rate?

EyePoint Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 4.51%, and for the last 5 years (2020-2024) was 25.66%.

What are EyePoint Pharmaceuticals’s revenue streams?

EyePoint Pharmaceuticals's revenue streams in c 24 are License And Collaboration Agreement, Product, Royalty, and Y U T I Q Product. License And Collaboration Agreement generated $38.5M in revenue, accounting 83.01% of the company's total revenue Product generated $3.16M in revenue, accounting 6.82% of the company's total revenue Royalty generated $1.61M in revenue, accounting 3.48% of the company's total revenue Y U T I Q Product generated $3.1M in revenue, accounting 6.68% of the company's total revenue, down -89.06% year-over-year.

What is EyePoint Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of EyePoint Pharmaceuticals was License And Collaboration Agreement. This segment made a revenue of $38.5M, representing 83.01% of the company's total revenue.